We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 22, 2021

Pembrolizumab vs Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Pembrolizumab Versus Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE-204): An Interim Analysis of a Multicentre, Randomised, Open-Label, Phase 3 Study
Lancet Oncol 2021 Mar 12;[EPub Ahead of Print], J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, R Gasiorowski, NA Johnson, LM Fogliatto, I Goncalves, JSR de Oliveira, V Buccheri, GF Perini, N Goldschmidt, I Kriachok, M Dickinson, M Komarnicki, A McDonald, M Ozcan, N Sekiguchi, Y Zhu, A Nahar, P Marinello, PL Zinzani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading